Īrija - angļu - HPRA (Health Products Regulatory Authority)

solvay chemicals international s.a - hydrogen peroxide - concentrate for solution for fish treatment - 49.5 percent weight/weight - hydrogen peroxide - atlantic salmon - miscellaneous

Īrija - angļu - HPRA (Health Products Regulatory Authority)

solvay chemicals international s.a - hydrogen peroxide - concentrate for solution for fish treatment - 49.5 %w/w - hydrogen peroxide - fish - (atlantic) salmon - miscellaneous

Malta - angļu - Medicines Authority

abbott healthcare products b.v. - mebeverine hydrochloride 200 mg - prolonged-release capsule

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

physicians total care, inc. - eprosartan mesylate (unii: 8n2l1nx8s3) (eprosartan - unii:2kh13z0s0y), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - eprosartan 600 mg - teveten® hct is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensives such as calcium channel blockers. this fixed dose combination is not indicated for initial therapy (see dosage and administration ). teveten® hct is contraindicated in patients who are hypersensitive to this product or any of its components. because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

physicians total care, inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - progesterone 100 mg - prometrium capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. they are also indicated for use in secondary amenorrhea. prometrium capsules should not be used in women with any of the following conditions: - prometrium capsules should not be used in patients with known hypersensitivity to its ingredients. prometrium capsules contain peanut oil and should never be used by patients allergic to peanuts. - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - liver dysfunction or disease. - known or suspected pregnancy. there is no indication for prometrium capsules in pregnancy. there appears to be little or no increased risk of birth defects in chi

Īrija - angļu - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - pancreatin - gastro-resistant capsule, hard - 300 milligram(s) - enzyme preparations; multienzymes (lipase, protease etc.)

Īrija - angļu - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - pancreas powder - gastro-resistant capsule, hard - 10000 - enzyme preparations; multienzymes (lipase, protease etc.)

Kanāda - angļu - Health Canada

solvay pharma inc - dronabinol - capsule - 10mg - dronabinol 10mg - miscellaneous antiemetics

Kanāda - angļu - Health Canada

solvay pharma inc - eprosartan (eprosartan mesylate) - tablet - 300mg - eprosartan (eprosartan mesylate) 300mg - angiotensin ii receptor antagonists

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

stat rx usa llc - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 150 mg - major depressive disorder: bupropion hydrochloride extended-release tablets (xl) are indicated for the treatment of major depressive disorder. the efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the major depression category of the apa diagnostic and statistical manual (dsm) (see clinical trials). a major depressive episode (dsm-iv) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired c